Evotec SE (EVO) News
Follow Evotec SE (EVO) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 30 public stories across 18 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
Evotec Reports Q3 and Nine-Month 2026 Results
Evotec reported group revenue of €164.9 million for Q3 and €465.0 million for the first nine months of 2026.
EQUITY | Nov 05, 2026, 07:18 AM UTC
M
Evolution AB Reports Q3 Revenue of €526M; Brazil Studio Temporarily Closed
Evolution AB reported Q3 revenue of €526 million and said its Brazil studio was temporarily closed.
EQUITY | Oct 23, 2026, 07:01 AM UTC
M
Evolution Q3 Revenue Slightly Misses Estimates as Margin Declines
EQUITY | Oct 23, 2026, 05:39 AM UTC
M
Evolution Reports Q3 Revenue of €526.1M, EBITDA of €345.9M
Evolution reported Q3 2026 revenue up 3.7% year over year and adjusted EBITDA at a 65.8% margin. It temporarily closed its Brazilian studio following a regulatory rollback.
EQUITY | Oct 23, 2026, 05:30 AM UTC
L
Evolution AB (publ) (EVO) Cancels 16.17M Treasury Shares; Share Count 183.06M
Evolution AB (publ) completed cancellation of 16,168,492 treasury shares in September 2026. As of 30 Sep 2026, total shares and votes are 183,058,121.Material DetailsContext by AI AnalystThis is a late-stage confirmation
EQUITY | Sep 30, 2026, 05:15 AM UTC
L
Evotec Announces Chief Scientific Officer Transition
HAMBURG, Germany, Sept. 29, 2026 // -- Evotec SE (NASDAQ:EVO) (Frankfurt Prime Standard: EVT) today announced that Chief Scientific Officer (CSO) Dr. Cord Dohrmann will step down effective September 30, 2026. The decisio
NEWS | Sep 29, 2026, 06:05 AM UTC
L
Embark Early Education Acquired 250,000 Ordinary Shares In Mayfield Childcare
Embark Early Education Ltd ASX:EVO
EQUITY | Sep 29, 2026, 01:48 AM UTC
L
Evolution AB (publ) (EVO) Buys Back 624,484 Shares; Holding Now 16.6M
Evolution AB (publ) repurchased 624,484 shares during Sep 21—25, 2026 under its buyback. It now holds 16,615,584 own shares out of 199,226,613. Since May 19, 2026, 16,615,584 shares have been bought toward a maximum of 1
EQUITY | Sep 28, 2026, 08:20 AM UTC
L
Acquisitions of own shares in Evolution AB (publ)
Evolution AB (publ) (“Evolution”) has, during the period 07 September 2026 — 11 September 2026, acquired a total of 830,973 own shares within the framework of the repurchase program introduced by the board of directors t
EQUITY | Sep 14, 2026, 06:01 AM UTC
M
Evotec subsidiary moves JST-018 orthopoxvirus antibodies into Phase 1
First-in-human Phase 1 study has started for investigational orthopoxvirus antibodies developed under the U.S. Department of War Accelerated Antibodies Program, supporting biodefense countermeasures.
GEOPOLITICS | Sep 09, 2026, 06:39 AM UTC
L
Evotec Biologics advances orthopoxvirus antibodies into Phase 1
Evotec Biologics advanced U.S. Department of War antibodies against orthopoxvirus into Phase 1 clinical studies.
GEOPOLITICS | Sep 09, 2026, 06:01 AM UTC
L
Playtech says Spectrum Report validates Black Cube investigation filing
Playtech said a Spectrum Report validates Black Cube’s filing submitted in connection with its ongoing litigation involving Evol.
EQUITY | Sep 09, 2026, 06:01 AM UTC
L
Evolution AB buys 842,025 own shares in repurchase program
Evolution AB acquired 842,025 own shares during 31 August 2026—04 September 2026 under its board-introduced repurchase program to optimize capital structure by reducing capital.
EQUITY | Sep 07, 2026, 06:30 AM UTC
L
EVO - Evotec and Plectonic Enter Research Collaboration to Explore New Generation of T-Cell-Engaging Approaches for Solid Tumors - Click For
EVO - Evotec and Plectonic Enter Research Collaboration to Explore New Generation of T-Cell-Engaging Approaches for Solid Tumors
EQUITY | Sep 02, 2026, 06:05 AM UTC
L
Evotec and Plectonic launch research collaboration for solid tumors immunotherapy
Evotec SE and Plectonic Biotech announced a research collaboration to explore a novel immunotherapy approach for solid tumors.
EQUITY | Sep 02, 2026, 06:05 AM UTC
L
Canaccord Genuity cuts Embark Early Education target to A$0.63
Canaccord Genuity cut its Embark Early Education price target by 42% to A$0.63 a share.
EQUITY | Sep 02, 2026, 01:06 AM UTC
L
Evolution AB (publ) acquires its own shares
Evolution AB (publ) has acquisitions of its own shares, according to TradingView News.
EQUITY | Aug 31, 2026, 06:20 AM UTC
L
Weekly Recap: Treasury share cancellation and Citibank buybacks
Weekly Recap: Treasury share cancellation and Citibank buybacks
RATES | Aug 31, 2026, 05:14 AM UTC
L
Evolution AB (Publ) issues notice of extraordinary general meeting
Evolution AB (Publ) has issued a notice for an extraordinary general meeting.
EQUITY | Aug 28, 2026, 06:00 AM UTC
M
EVO reports $12.74M statutory loss as revenue falls 4.4% YoY
EVO posted a $12.74 million statutory loss, driven by impairments, with revenue down 4.4% year over year.
EQUITY | Aug 27, 2026, 11:01 PM UTC
L
Evotec reaffirms FY2026 sales guidance range of $667.470M–$714.310M
Evotec (NASDAQ: EVO) affirms FY2026 sales outlook of $667.470 million–$714.310 million, unchanged, versus a $673.750 million estimate.
EARNINGS | Aug 13, 2026, 08:49 AM UTC
M
Evotec Enters AI R&D Collaboration
Evotec collaborates with Odyssey Therapeutics
EQUITY | Aug 06, 2026, 06:18 AM UTC
L
EVO downgraded from Buy to Hold @ Berenberg
EVO downgraded from Buy to Hold @ Berenberg
EQUITY | Jul 16, 2026, 11:12 AM UTC
H
Phoenix Education Partners, Pentair And Other Big Stocks Moving Lower In Wednesday’s Pre-Market Session
U.S. stock futures were mostly higher this morning, with the Nasdaq 100 futures gaining around 100 points on Wednesday. Shares of Phoenix Education Partners Inc (NYSE: PXED ) fell sharply in pre-market trading after the
EARNINGS | Jul 15, 2026, 12:02 PM UTC
L
EVO Downgrade from Buy to Hold W/$2.00 PT (from $4.00) at TD Cowen
EVO Downgrade from Buy to Hold W/$2.00 PT (from $4.00) at TD Cowen
EQUITY | Jul 15, 2026, 11:47 AM UTC
L
EVO downgraded from Buy to Hold @ TDCowen
EVO downgraded from Buy to Hold @ TDCowen
EQUITY | Jul 15, 2026, 11:10 AM UTC
H
EVO (more) Preliminary H1 2026 results: Group revenues of approximately €300.1M and adjusted Group EBITDA of approximately -€42.7M; full H1
EVO (more) Preliminary H1 2026 results: Group revenues of approximately €300.1M and adjusted Group EBITDA of approximately -€42.7M; full H1 2026 financial results to be published on August 13, 2026, as scheduled Updated
MACRO | Jul 14, 2026, 11:37 AM UTC
H
EVO -13% after results, guidance
EVO -13% after results, guidance
EARNINGS | Jul 14, 2026, 11:36 AM UTC
H
Evotec Now Expects FY26 Revenue From €700M - €780M To ~€570M - €610M, Expects H1 Revenue Of ~€300.1M
Evotec SE (NASDAQ: EVO ) (Frankfurt Prime Standard: EVT) today announced preliminary unaudited financial results for the second quarter and first half of 2026 and updated its full-year 2026 outlook. Full financial result
EARNINGS | Jul 13, 2026, 07:50 PM UTC
H
EVO Evotec announces preliminary second quarter and first half 2026 results and updates full-year 2026 outlook Evotec Se - expects h1 2026 g
EVO Evotec announces preliminary second quarter and first half 2026 results and updates full-year 2026 outlook Evotec Se - expects h1 2026 group revenues of €300.1M and adj group EBITDA of -€42.7M - Previous guidance was
EARNINGS | Jul 13, 2026, 07:20 PM UTC